During the recent session, Gilead Sciences, Inc. (NASDAQ:GILD)’s traded shares were 2.47 million, with the beta value of the company hitting 0.23. At the last check today, the stock’s price was $65.00, reflecting an intraday loss of -0.42% or -$0.27. The 52-week high for the GILD share is $87.86, that puts it down -35.17 from that peak though still a striking -0.14% loss since the share price plummeted to a 52-week low of $65.09. The company’s market capitalization is $81.05B, and the average trade volume was 7.32 million shares over the past three months.
Gilead Sciences, Inc. (NASDAQ:GILD) trade information
Gilead Sciences, Inc. (GILD) registered a -0.42% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.42% in intraday trading to $65.00, hitting a weekly high. The stock’s 5-day price performance is -2.64%, and it has moved by -10.98% in 30 days. Based on these gigs, the overall price performance for the year is -22.38%.
Gilead Sciences, Inc. (GILD) estimates and forecasts
Statistics show that Gilead Sciences, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Gilead Sciences, Inc. (GILD) shares have gone down -17.09% during the last six months, with a year-to-date growth rate less than the industry average at -37.50% against 12.90. In the rating firms’ projections, revenue will increase 1.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.77B as predicted by 20 analyst(s). Meanwhile, a consensus of 20 analyst(s) estimates revenue growth to 7.07B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 6.6B and 6.8B respectively. In this case, analysts expect current quarter sales to grow by 2.70% and then jump by 3.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.55%. While earnings are projected to return -43.72% in 2024, the next five years will return 5.38% per annum.
GILD Dividends
Gilead Sciences, Inc. is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Gilead Sciences, Inc. is 3.02, with the dividend yield indicating at 4.65 percent, continuing the trend of increasing dividends in recent years.
